Millennium Management’s Ibere Pharmaceuticals IBER Stock Holding History

Millennium Management’s Portfolio IBER Stock Details IBER Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q1	–	Sell	-660,664	Closed	-$6.67M	–	7340
2022 Q4	$6.67M	Buy	660,664 +8,000	+1%	+$80K	﹤0.01%	2548
2022 Q3	$6.47M	Buy	652,664 +188,697	+41%	+$1.86M	﹤0.01%	2645
2022 Q2	$4.55M	Buy	463,967 +22,090	+5%	+$217K	﹤0.01%	2903
2022 Q1	$4.33M	Sell	441,877 -3,270	-0.7%	-$31.9K	﹤0.01%	3091
2021 Q4	$4.33M	Buy	445,147 +109,157	+32%	+$1.06M	﹤0.01%	3049
2021 Q3	$3.26M	Buy	335,990 +104,000	+45%	+$1.01M	﹤0.01%	3361
2021 Q2	$2.24M	Buy	+231,990	New	+$2.26M	﹤0.01%	3827

Millennium Management's IBER Position: Q1 2023 in Review

Millennium Management sold out of Ibere Pharmaceuticals (IBER) in Q1 2023, closing a stake of 660,664 shares — an estimated $6.67M sold.

Millennium Management first reported a position in IBER in Q2 2021 and held it in 7 quarters. The position peaked at $6.67M in Q4 2022. 0 funds tracked by Wall St. Rank hold IBER as of Q1 2023.

Millennium Management reported no remaining Ibere Pharmaceuticals position as of Q1 2023 after selling out during the quarter.
Millennium Management sold 660,664 Ibere Pharmaceuticals shares in Q1 2023, an estimated $6.67M.
Millennium Management first reported a position in Ibere Pharmaceuticals in Q2 2021 and held it in 7 quarters.
Millennium Management's Ibere Pharmaceuticals position peaked at $6.67M in Q4 2022.
0 funds tracked by Wall St. Rank held Ibere Pharmaceuticals as of Q1 2023.

Based on Millennium Management's 13F filing for Q1 2023, filed 15 May 2023.